Related Experiment Videos
Cloning and analysis of the Epstein-Barr virus glycoprotein 350 genes
1Faculty of Biological Sciences and The Institute for Molecular Biology and Genetics, Chonbuk National University, Chonju, Korea.
Abstract:
Membrane glycoprotein 350 (gp350) of the Epstein-Barr virus (EBV) is considered as a major target for vaccine development, since the gp350 has been identified as the virus' mediator for receptor interaction and as an inducer of specific in vitro virus-neutralizing antibodies. In an initial attempt to develop an effective DNA vaccine against an EBV infection, gp350 genes were isolated from SNU-20 and SNU-1103 which are the EBV-infected lymphoblastoid cell lines established in Korea. In addition, the nucleotide sequences of the gp350 genes were determined and compared with those of other EBV strains such as B95-8, P3HR-1/AG876 and M81. Sequence analysis showed that similar high degrees of homology between 2 EBV strains derived from African Burkitt's lymphoma, P3HR-1 and AG876, was shown between the gp350 genes isolated from 2 EBV-infected lymphoblastoid cell lines established in Korea. Furthermore, these 2 Korean and 2 African strains displayed nearly identical patterns of sequence variations from B95-8. In addition, the sequence of the isolated gp350 genes, which have been reported to be associated with the biology of EBV infection, is analyzed.
Insights
Epstein-Barr virus (EBV) membrane glycoprotein 350 (gp350) is crucial for EBV infection. This study analyzes gp350 gene sequences from Korean EBV strains, revealing high homology with African strains, important for vaccine development.
Area of Science:
- Virology
- Molecular Biology
- Vaccine Development
Background:
- Epstein-Barr virus (EBV) membrane glycoprotein 350 (gp350) is a key target for vaccine development.
- gp350 mediates viral entry and elicits neutralizing antibodies.
- EBV infection is widespread and associated with various cancers.
Purpose of the Study:
- To isolate and analyze the gp350 gene sequences from Korean EBV strains.
- To compare these sequences with other known EBV strains.
- To assess the potential of these gp350 genes for DNA vaccine development.
Main Methods:
- Isolation of gp350 genes from Korean EBV-infected lymphoblastoid cell lines (SNU-20, SNU-1103).
- Determination of nucleotide sequences of the isolated gp350 genes.
- Comparative sequence analysis with EBV strains B95-8, P3HR-1/AG876, and M81.
Main Results:
- High sequence homology was observed between gp350 genes from Korean EBV strains and African EBV strains (P3HR-1, AG876).
- The Korean and African strains showed nearly identical sequence variation patterns compared to the B95-8 strain.
- Sequence analysis provides insights into the biological relevance of gp350 in EBV infection.
Conclusions:
- Korean EBV gp350 gene sequences are highly homologous to those of African strains.
- These findings support the potential of Korean EBV gp350 as a target for vaccine development.
- Further analysis of gp350 sequence variations can inform EBV vaccine strategies.